Bristol Myers Squibb (BMY) closed at $72.45 in the latest trading session, marking a -0.74% move from the prior day.
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Originally published on Bristol Myers Squibb News & Perspectives